The European Commission is considering unilaterally expanding the scope of its authorities.

The European Union’s antitrust authority on Friday said it was considering changes to its merger review rules to include a wider swath of technology and pharmaceutical deals that normally wouldn’t fall within its purview but could possibly harm the bloc’s internal market.

…the European Commission said it was fielding opinions from the public on whether the regulator should also probe mergers involving companies with smaller revenues.

Because instructing the big companies on the business decisions the Commission would permit them to take doesn’t have enough juice for them anymore.

Such a move would be especially significant for the digital and pharmaceutical sectors, the EU said, where an acquired company might generate little turnover but holds commercially valuable data or owns products under development that haven’t yet been marketed.

That’s an area of regulatory vacuum, and we can’t have that, now can we?  Besides those data and nascent products represent action on which the EU wants its vig.